{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+injection+SC%2FIV", "query": { "intervention": "Placebo injection SC/IV" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 123, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+injection+SC%2FIV&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T07:31:20.427Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05132582", "title": "A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2 Positive Breast Cancer" ], "interventions": [ { "name": "Tucatinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Combination product: Trastuzumab + Pertuzumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 654, "start_date": "2022-03-07", "completion_date": "2027-09-28", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-10T07:31:20.427Z", "location_count": 76, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 45 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05132582" }, { "nct_id": "NCT04554966", "title": "Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Immunodeficiency Virus (HIV)" ], "interventions": [ { "name": "ABBV-382", "type": "DRUG" }, { "name": "Placebo for ABBV-382", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 54, "start_date": "2021-04-16", "completion_date": "2023-08-14", "has_results": false, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-09-10T07:31:20.427Z", "location_count": 19, "location_summary": "Bakersfield, California • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ft. Pierce", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04554966" }, { "nct_id": "NCT02601625", "title": "A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Safety", "Pharmacokinetics", "Healthy Subjects" ], "interventions": [ { "name": "Anifrolumab SC injection (300mg)", "type": "DRUG" }, { "name": "Anifrolumab IV infusion (300mg)", "type": "DRUG" }, { "name": "Anifrolumab SC infusion (600mg)", "type": "DRUG" }, { "name": "Anifrolumab placebo SC injection (300mg)", "type": "DRUG" }, { "name": "Anifrolumab placebo IV infusion (300mg)", "type": "DRUG" }, { "name": "Anifrolumab placebo SC infusion (600mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 30, "start_date": "2015-11-16", "completion_date": "2016-05-25", "has_results": true, "last_update_posted_date": "2019-02-26", "last_synced_at": "2026-09-10T07:31:20.427Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02601625" }, { "nct_id": "NCT03398148", "title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Ulcerative Colitis (UC)" ], "interventions": [ { "name": "risankizumab IV", "type": "DRUG" }, { "name": "placebo for risankizumab", "type": "DRUG" }, { "name": "risankizumab SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 1558, "start_date": "2018-03-07", "completion_date": "2023-05-11", "has_results": true, "last_update_posted_date": "2025-01-16", "last_synced_at": "2026-09-10T07:31:20.427Z", "location_count": 82, "location_summary": "Coronado, California • Irvine, California • La Jolla, California + 63 more", "locations": [ { "city": "Coronado", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03398148" }, { "nct_id": "NCT04590586", "title": "Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Standard of care", "type": "DRUG" }, { "name": "Apremilast", "type": "DRUG" }, { "name": "Apremilast placebo", "type": "DRUG" }, { "name": "Lanadelumab", "type": "DRUG" }, { "name": "Lanadelumab placebo", "type": "DRUG" }, { "name": "Zilucoplan", "type": "DRUG" }, { "name": "Zilucoplan placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 515, "start_date": "2020-11-24", "completion_date": "2021-08-03", "has_results": true, "last_update_posted_date": "2022-06-29", "last_synced_at": "2026-09-10T07:31:20.427Z", "location_count": 21, "location_summary": "Anniston, Alabama • Bakersfield, California • Chula Vista, California + 17 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "El Centro", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04590586" }, { "nct_id": "NCT01147341", "title": "Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Cimzia", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael Schiff, MD", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 37, "start_date": "2010-07", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-09-10T07:31:20.427Z", "location_count": 12, "location_summary": "Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147341" }, { "nct_id": "NCT06032546", "title": "A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Immuno-deficiency Virus (HIV) Disease" ], "interventions": [ { "name": "Budigalimab", "type": "DRUG" }, { "name": "Placebo for Budigalimab", "type": "DRUG" }, { "name": "ABBV-382", "type": "DRUG" }, { "name": "Placebo for ABBV-382", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 163, "start_date": "2023-10-12", "completion_date": "2025-09-22", "has_results": false, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-09-10T07:31:20.427Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06032546" }, { "nct_id": "NCT05068284", "title": "A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "ABBV-154", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 176, "start_date": "2022-01-31", "completion_date": "2023-07-20", "has_results": true, "last_update_posted_date": "2024-10-03", "last_synced_at": "2026-09-10T07:31:20.427Z", "location_count": 45, "location_summary": "Dothan, Alabama • Mobile, Alabama • Coronado, California + 38 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Coronado", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05068284" }, { "nct_id": "NCT05354349", "title": "Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PRA023 IV Low Dose", "type": "DRUG" }, { "name": "PRA023 SC", "type": "DRUG" }, { "name": "Placebo IV", "type": "DRUG" }, { "name": "Placebo SC", "type": "DRUG" }, { "name": "PRA023 IV High Dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 49, "start_date": "2022-04-06", "completion_date": "2022-08-31", "has_results": false, "last_update_posted_date": "2024-01-16", "last_synced_at": "2026-09-10T07:31:20.427Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05354349" }, { "nct_id": "NCT02663687", "title": "Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hereditary Angioedema (HAE)" ], "interventions": [ { "name": "Recombinant human C1 esterase inhibitor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "SHP623", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 48, "start_date": "2016-02-19", "completion_date": "2016-12-05", "has_results": true, "last_update_posted_date": "2021-06-03", "last_synced_at": "2026-09-10T07:31:20.427Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02663687" } ] }